Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM; ARCCS Study Investigators.
Stadler WM, et al. Among authors: bukowski rm.
Cancer. 2010 Mar 1;116(5):1272-80. doi: 10.1002/cncr.24864.
Cancer. 2010.
PMID: 20082451
Free article.